Dividendos de Sarepta Therapeutics

Dividendo controles de criterios 0/6

Sarepta Therapeutics no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$5.67
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Apr 15

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 11

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09

Sarepta: The DMD Leader

Apr 26

Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments

Feb 09

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Feb 07

A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dec 06

Sarepta: Revenue Keeps Rising While We Wait For Functional Data

Nov 01

Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Nov 01

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Jul 19

Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed

Jun 02

Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

May 27

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de SRPT han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de SRPT han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Sarepta Therapeutics vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de SRPT con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (SRPT)	n/a
Suelo de mercado 25% (US)	1.6%
Techo de mercado 25% (US)	4.8%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (SRPT)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de SRPT en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de SRPT en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de SRPT para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que SRPT no ha comunicado ningún pago.

Dividendos de Sarepta Therapeutics

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Board Member notifies of intention to sell stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 8.0% to US$162

Sarepta Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Forecast to breakeven in 2024

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Independent Chairwoman exercised options to buy US$1.2m worth of stock.

Independent Director recently bought US$3.9m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 21% to US$143

Sarepta Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

No longer forecast to breakeven

Insider recently bought US$3.7m worth of stock

Consensus estimates of losses per share improve by 22%

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Board Member notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sarepta Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Sarepta Therapeutics, Inc. Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Consensus EPS estimates upgraded to US$3.68 loss

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 13%

Price target increased by 11% to US$167

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Independent Chairwoman exercised options to buy US$2.6m worth of stock.

Sarepta Therapeutics Announces That U.S. FDA Has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’S Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Insider recently sold US$94k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Sarepta Therapeutics Submits Biologics License Application for Srp-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Insider recently bought US$6.0m worth of stock

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Food and Drug Administration Lifts its Clinical Hold on Sarepta Therapeutics's SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

Sarepta says FDA lifted clinical hold on Duchenne candidate

Insider recently bought US$5.0m worth of stock

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Consensus forecasts updated

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Sarepta Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies

Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors

Consensus forecasts updated

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Sarepta: The DMD Leader

Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat